Metoprolol (generic), Toprol XL News

WOODCLIFF LAKE, N.J. Generic drug maker Par Pharmaceutical had revenues of $294.8 million and profits of $26.3 million during third quarter 2009, the company announced in a financial report Friday.

Generic drugmaker Par Pharmaceutical Companies Inc. said Friday its profit surged in the third quarter on a boost in product sales.

Watson Pharmaceuticals, Inc. reported third quarter earnings of 66 cents per share, a cent above the Zacks Consensus Estimate.

The UK's second largest pharmaceutical company said revenues in the third quarter rose 5pc to $8.2bn and pre-tax profits 24pc to $3.03bn. On constant exchange rates, sales rose 10pc and around half of this was contributed by growth in the sales of Toprol-XL, the high blood pressure treatment which was expected to be hit by generic rivals, and $152m ...

David Brennan, the chief executive of AstraZeneca, was upbeat yesterday as he unveiled a 27 per cent jump in pre-tax profit for the third quarter - better than expected - and increased his forecast for the year.

LONDON Profits for AstraZeneca were up by 27% for third quarter 2009 compared with third quarter 2008, the Anglo-Swedish drug maker announced in an earnings report Thursday.

AstraZeneca Third quarter revenue increased by 10 percent at constant exchange rates to $8,200 million.

If you're one of the millions of Americans taking a medicine called a beta-blocker for high blood pressure, here are some basics about this family of medicines: -- Beta-blockers are a family of medicines also known as beta-adrenergic blocking agents.

Shortness of breath and fatigue are often symptoms of conditions like respiratory disease, but could also be side effects associated with certain medications .

Which outstanding government-run program is Obamacare's model: Amtrak, Fannie Mae, airport security, postal service, public education? Why did the Department of Veterans Affairs reject my prescription for Toprol XL while an evil, greedy, private insurance company provided 17 refills without question? If Obamacare's "public option" is superior to ...

Multinational Medicines - Ensuring Drug Quality in an Era of Global Manufacturing Susan Okie, M.D. Rickee Rudowitz, a 56-year-old New Jersey woman with hypertension, believes that a generic version of long-acting metoprolol played havoc with her health last year.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Applications for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Applications for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Applications for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Applications for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Applications for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths.

WOODCLIFF LAKE,A N.J. Generic drug maker Par Pharmaceutical Cos. got a jump in revenues and net income during second quarter 2009, the company announced in an earnings report Tuesday.

Watson Pharmaceuticals Inc. said Monday it received approval for a generic version of the high blood pressure and angina drug Toprol XL, and plans to begin shipping the product immediately.

AstraZeneca 2Q09 2Q Revenues: $8.0 billion 2Q Earnings: $2.4 billion YTD Revenues: $15.7 billion YTD Earnings: $4.0 billion Comments: Two generic marketers of Toprol-XL withdrew from the U.S. market,and the introduction of generic Casodex was delayed, giving AZ a boost.

Second quarter sales increased by 9 percent at constant exchange rates to $7,958 million.